BG-60366 in EGFR-mutant NSCLC: a chimeric degrader retired after 33 patients in a saturated landscape

What was tried

BG-60366 is an oral chimeric degradation-activation compound (CDAC) designed to ubiquitinate and destroy mutant EGFR, including the C797S resistance allele that defeats third-generation TKIs. The Phase 1a/1b first-in-human study NCT06685718 enrolled 33 participants with advanced or metastatic EGFR-mutant non-small cell lung cancer (NSCLC) who had progressed on prior third-generation EGFR TKIs, with a Phase 1a safety expansion restricted to patients carrying documented C797S resistance mutations. The trial was sponsored by BeOne Medicines, the company formerly known as BeiGene. Primary endpoints for Phase 1a were adverse events, maximum tolerated dose, and recommended dose for expansion. Phase 1b would have added overall response rate by investigator assessment per RECIST. Phase 1a opened. Phase 1a safety expansion and Phase 1b did not. The study was terminated on 21 April 2026 with the stated reason "Evaluation on business strategy, not involving safety issue."

The biological hypothesis

EGFR-mutant NSCLC patients who progress on osimertinib or lazertinib accumulate on-target resistance mutations, most prominently C797S, that abolish the covalent binding required by third-generation TKIs. A protein degrader does not need a closed binding pocket and can eliminate the resistant kinase entirely rather than inhibit it. The hypothesis behind BG-60366 was clean: bivalent recruitment of an E3 ligase to mutant EGFR should produce sub-stoichiometric, catalytic degradation that survives the binding-site mutations TKIs cannot. Preclinical EGFR PROTACs and CDACs have repeatedly shown activity against C797S-containing cells, including in published 2025 work on pomalidomide-based gefitinib PROTACs (Bioorg Chem) and probe-quality EGFR degraders covering wild-type and Del19 alleles (Bioorg Med Chem Lett). Open Targets reports an association score of 0.852 between EGFR and NSCLC, with clinical (0.996) and literature (0.999) evidence essentially saturated, so the target biology is not in doubt.

What actually happened

Thirty-three participants enrolled in Phase 1a dose escalation. Phase 1a safety expansion never opened. Phase 1b never opened. BeOne stated the termination was a strategic decision and explicitly not safety-driven. The company did not publicly report a recommended dose for expansion, an objective response rate, or pharmacodynamic readouts on tumor EGFR degradation. The competitive backdrop matters: by 2026 the EGFR-mutant NSCLC landscape included nine approved or near-approved on-target options (gefitinib, erlotinib, afatinib, dacomitinib, osimertinib, lazertinib, aumolertinib, furmonertinib, amivantamab), plus Phase 3 readouts for the HER3 antibody-drug conjugate patritumab deruxtecan and TROP2-ADC datopotamab deruxtecan. The post-osimertinib niche BG-60366 targeted was simultaneously being claimed by amivantamab plus chemotherapy and ADC combinations.

Failure mechanism, best guess

"Business strategy" is a deliberately uninformative label, but the public record is not silent. Three explanations fit the disclosure: a thin therapeutic index in dose escalation that pushed the predicted Phase 1b dose below the level required for meaningful EGFR knockdown, underwhelming response signals across 33 patients that failed to differentiate BG-60366 from amivantamab plus chemotherapy, and a portfolio judgement that the post-osimertinib niche is shrinking as 1L combination regimens push more patients onto multi-mechanism therapy before they ever reach a C797S-only setting. The disclosed status, no Phase 1a safety expansion despite C797S enrichment criteria already written into the protocol, points away from a pure operational shutdown and toward a mechanistic verdict on differentiation rather than safety.

How to prevent this next time

Phase 1 EGFR degrader programs should set explicit posterior-probability-of-success gates before opening dose expansion. With a Phase 1 confirmed-response rate prior centred at 25% (the historical osimertinib-refractory benchmark for amivantamab combinations) and a decision threshold of 30% to justify expansion, a Bayesian futility analysis at n=20 would have made the strategic call quantitative rather than narrative. The relevant integral is

PP(success)=∫θ​P(final success∣θ,interim data)⋅π(θ∣interim data)dθ

Two additional changes would have helped. First, mandate biomarker enrichment by C797S allele frequency and by quantitative on-treatment EGFR protein knockdown in paired tumor or circulating tumor DNA samples. Degraders without demonstrated pharmacodynamic knockdown in the relevant resistance setting cannot survive a competitive landscape that includes drugs with documented response rates. Second, run a structured competitive landscape red-team at the start of every degrader Phase 1 in saturated kinase targets, with explicit numeric assumptions about what response rate would beat the 12 to 18 month standard-of-care option available to those same patients in 2027 and 2028. The single highest leverage change would have been a pre-specified Bayesian futility rule at n=20 that converted any expansion decision into a posterior probability the development committee could defend numerically.

What this means for similar programs

Open Targets lists EGFR with 0.852 NSCLC association, the highest disease tie in its profile, and EGFR sits in the densest documented programmatic landscape in oncology. The Claidex Mechanism Risk Score for EGFR is 27 (yellow band), driven mostly by programmatic saturation rather than recorded failures. A degrader is biologically reasonable here but operationally hard: the comparator standard is moving every 12 to 18 months, and a single Phase 1 readout cannot keep up with that pace unless the trial is enrichment-defined and powered against a moving benchmark. Programs targeting EGFR or other kinases with established TKIs should treat the standard-of-care trajectory as a moving inclusion criterion, not a fixed comparator.

Open questions

Did dose escalation reach a biologically active dose, defined by quantitative EGFR degradation in tumor or ctDNA? Were any objective responses observed among the 33 enrolled participants, and if so in which EGFR genotype? Did BeOne disclose any pharmacokinetic limits, such as oral bioavailability or hepatic CYP-mediated clearance, that constrained achievable plasma exposure? Does BeOne retain the BG-60366 chemical matter for repositioning to other EGFR-driven settings such as glioblastoma or HER family-amplified solid tumors, where the competitive landscape is materially less crowded?

Sources

1. ClinicalTrials.gov, NCT06685718, full record retrieved 2026-05-22. Open Targets Platform v25.06, target EGFR (ENSG00000146648), associated disease EFO_0003060 (NSCLC), retrieved 2026-05-22. Open Targets datatype scores for EGFR in NSCLC: clinical 0.996, literature 0.999, somatic mutation 0.832, affected pathway 0.821, genetic association 0.746. ChEMBL target CHEMBL203 (EGFR, single protein, UniProt P00533). OpenFDA FAERS osimertinib top reactions (counts): death 1601, malignant neoplasm progression 1259, drug resistance 831, diarrhoea 404, rash 259. Probe-quality EGFR degraders covering wild-type and Del19 alleles, Bioorg Med Chem Lett 2026,Pomalidomide-based gefitinib PROTAC against TKI-resistant lung cancer, Bioorg Chem 2025,Amiloride synergizes with EGFR PROTACs to overcome resistance in NSCLC, Bioorg Chem 2025,EGFR CAR-NK and CAR-T cells against EGFR-inhibitor-resistant NSCLC, Clin Cancer Res 2025,Targeting TROP2 with CAR-T to eradicate drug-tolerant persisters in EGFR-mutant NSCLC, Cancer Discov 2025,. Available from: https://clinicaltrials.gov/study/NCT06685718.